XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan

Stock News

04/12

XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1165876354"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165876354\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165876354?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-12 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165876354","market":"nz","top_or_hot":-1,"title":"XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan","media":"Stock News","content":"<p>XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanZhu Bio-B Receives Regulatory Approval for H-Share Full Circulation Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-12 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1165876354","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165876354","pubTimestamp":1775988373,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02575":"轩竹生物-B"},"translate_title":"轩竹生物-B H股全流通方案获监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1},"content_text":"XuanZhu Bio-B (02575) has announced that it recently received a formal filing notice from the China Securities Regulatory Commission regarding its application for an H-share full circulation plan. According to the notice, the company has completed the CSRC filing process for the conversion of a total of 357,245,794 non-traded shares held by six shareholders into 357,245,794 H-shares on a one-for-one basis. These 357,245,794 H-shares will be listed and traded on the main board of the Hong Kong Stock Exchange upon completion of the conversion process and after the exchange grants listing approval. The notice remains valid for 12 months starting from the CSRC approval date of March 26, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}